ERBB2 and neoplasm: Furthermore, from a case report of a patient with ER+/HER2– mBC treated with alpelisib plus fulvestrant who achieved a partial response, molecular profiling revealed that both the primary tumor and metastatic lesions harbored multiple PIK3CAmut [29].